XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer Mar 18, 2013 1:00pm EDT
XOMA Reports 2012 Operational Highlights and Fourth Quarter and Full-Year Financial Results Mar 12, 2013 4:05pm EDT
XOMA Announces Fourth Quarter and Full-Year Financial Results Conference Call Mar 04, 2013 1:30pm EST
XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris Jan 07, 2013 8:00am EST
XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program Dec 31, 2012 8:00am EST
XOMA Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome Nov 29, 2012 8:00am EST
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Nov 20, 2012 4:05pm EST
XOMA Initiates Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic Treatment Oct 03, 2012 4:00pm EDT
